UroGen Wins First FDA Approval With Jelmyto For Urothelial Cancer

Jelmyto relies on a proprietary sustained-release drug delivery technology that UroGen plans to use for future drugs. The company is moving ahead with a launch in June, relying on virtual technology. 

UroGen Pharma Ltd. is launching its first commercial drug following the US Food and Drug Administration approval of Jelmyto (mitomycin) for adults with low-grade upper tract urothelial cancer (LG UTUC). The company announced the approval after market close on 15 April and said it will aim to launch the drug on 1 June despite the ongoing COVID-19 pandemic.

"None of us could have anticipated that we would be executing a launch in the middle of a pandemic," CEO...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from New Products

More from Scrip